Intervention Protocol

You have free access to this content

Antiviral agents for hepatitis B virus-related cirrhosis

  1. Edmond Atallah1,*,
  2. Layli Eslami2,
  3. Khatereh Isazadehfar3

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 27 FEB 2014

DOI: 10.1002/14651858.CD011002


How to Cite

Atallah E, Eslami L, Isazadehfar K. Antiviral agents for hepatitis B virus-related cirrhosis (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD011002. DOI: 10.1002/14651858.CD011002.

Author Information

  1. 1

    Mid Cheshire Hospitals NHS Foundation Trust, Leighton Hospital, Crewe, Cheshire, UK

  2. 2

    Golestan University of Medical Science, Taleghani Hospital, Gonbad e Kavous, Golestan province, Iran

  3. 3

    Ardabil University of Medical Sciences, Department of Community Medicine, Ardabil, Ardabil, Iran

*Edmond Atallah, Leighton Hospital, Mid Cheshire Hospitals NHS Foundation Trust, Middlewich Road, Crewe, Cheshire, CW1 4QJ, UK. edmond.atallah@doctors.org.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 27 FEB 2014

SEARCH

References

Additional references

Belongia 2008
  • Belongia EA, Costa J, Gareen IF. NIH consensus development statement on management of hepatitis B. NIH Consensus and State-of-the-Science Statements 2008;25:1-29.
Brok 2008
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
Brok 2009
  • Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
Chang 2010
Chen 2007
  • Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B. Hepatology International 2007;1:267-73.
CTU 2011
  • Copenhagen Trial Unit. TSA - Trial Sequential Analysis, 2011. ctu.dk/tsa/ (accessed 14 January 2014).
De Jongh 1992
  • De Jongh FE, Janssen HL, de Man RA. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5.
DeMets 1987
DerSimonian 1986
Dienstag 2003
EASL 2012
  • European Association for the Study of the Liver. EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. Journal of Hepatology 2012;57:167-85.
Egger 1997
Fernandez 2001
Gluud 2013
  • Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 7. Art. No.: LIVER.
Hadziyannis 2006
  • Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hollis 1999
ICH-GCP 1997
  • International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
Kamath 2001
Keeffe 2006
  • Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clinical Gastroenterology and Hepatology 2006;4:936-62.
Kjaergard 2001
Lavanchy 2004
Liaw 2004
Liaw 2008
  • Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B. Hepatology International 2008;2:263-83.
Liaw 2012
  • Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B. Hepatology International 2012;6(3):531-61.
Lok 2007
Lok 2009
Lundh 2012
Malinchoc 2000
Moher 1998
  • Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
Perrillo 1995
  • Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995;109:908-16.
Perz 2006
  • Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 2006;45:529-38.
Pugh 1973
RevMan 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Royle 2003
  • Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
Savović 2012
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
Savović 2012a
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273(5):408-12.
Schuppan 2008
Thorlund 2009
  • Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
Thorlund 2010
  • Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
Thorlund 2011
  • Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 14 January 2014).
Thorlund 2011a
  • Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PLoS One 2011;6(10):e25491.
Wetterslev 2008
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
Wetterslev 2009
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology 2009;9:86.
Whitfield 2010
  • Whitfield K, Stoey LS, Skoog M, Lindschou Hansen J, Mumtaz K, Gluud C. Levamisole for chronic hepatitis B. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD008845]
Wiesner 2003
Wood 2008
  • Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;366:601-5.
Zhao 2010
  • Shushan Zhao, Lanhua Tang, Xuegong Fan, Lizhang Chen. Telbivudine for chronic hepatitis B. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD008715]